Latest News on TWST

Financial News Based On Company


Advertisement
Advertisement

Twist Bioscience (TWST) accounting chief had to sell 1,637 shares to cover tax withholding.

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-59790cdfa7f4.html
Robert F. Werner, Chief Accounting Officer at Twist Bioscience Corp (TWST), sold 1,637 common shares at $103.688 per share on November 16, 2026. This sale was a non-discretionary transaction required to cover tax withholding obligations related to the vesting of Performance Stock Units. Werner also received an award of 3,641 restricted stock units on the same date, which will vest quarterly over 48 months, subject to continuous service.

To cover taxes on vested performance shares, the CFO of Twist Bioscience (TWST) had to sell 6,359 shares.

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-1b3eb996b605.html
Adam Laponis, CFO of Twist Bioscience (TWST), sold 6,359 common shares on November 16, 2026, at $103.6880 per share. This "sell to cover" transaction was mandatory to fulfill tax withholding obligations tied to the vesting of Performance Stock Units and was not a discretionary trade. Additionally, Laponis received a restricted stock unit (RSU) award of 7,828 shares, which will vest quarterly over 48 months.

TWST: AI drug discovery and high-sensitivity MRD are emerging growth drivers, with capacity key

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4664612:0-twst-ai-drug-discovery-and-high-sensitivity-mrd-are-emerging-growth-drivers-with-capacity-key/
Twist Bioscience (TWST) is seeing significant growth in AI drug discovery, with revenue projected to reach at least $100M in 2027, up from $59M in 2026. The company's silicon-chip DNA synthesis supports a substantial serviceable market, and capacity is identified as a key factor in future growth. This information is based on an AI-generated summary of a Jefferies Global Healthcare Conference Audio Transcript from November 17, 2026.

Form 144 Twist Bioscience Corp For: 16 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-twist-bioscience-corp-for-16-november-93CH-4961954
Investing.com reported on a Form 144 filing for Twist Bioscience Corp (TWST) on November 16, 2026. The article notes the stock's performance, showing a -5.88% change, and was published by Investing.com's financial markets news section.

Twist Bioscience FY 2026: Revenue $459.43M, EPS ($2.08) — 10-K Summary

https://www.tradingview.com/news/tradingview:7844f1dce263a:0-twist-bioscience-fy-2026-revenue-459-43m-eps-2-08-10-k-summary/
Twist Bioscience reported a 22% year-over-year revenue increase to $459.43 million for FY 2026, driven by growth in DNA Synthesis, Protein Solutions, and NGS Applications. Despite revenue growth, the company's net loss widened significantly to $130.2 million, resulting in a diluted EPS of ($2.08). The company plans to invest approximately $150 million in capital expenditures over the next two fiscal years to support an annual revenue target exceeding $1.0 billion.
Advertisement

A proposed 5,427-share sale at Twist Bioscience (TWST) includes shares to cover an officer’s tax obligation.

https://www.stocktitan.net/sec-filings/TWST/144-twist-bioscience-corp-sec-filing-aa8ec512c8d7.html
Dennis H. Cho, an officer at Twist Bioscience (TWST), has filed a notice for the proposed sale of 5,427 common shares, valued at approximately $562,716.95, with an anticipated sale date of November 16, 2026. These shares were acquired through restricted-stock vesting and the sale includes an amount specifically designated to cover a tax obligation from a vested equity award distribution. The company has 62,707,424 shares outstanding, and the notice also details six previous sales made by Cho between August 19 and November 3.

60% of Twist Bioscience (TWST) stock award vests September 30, 2027, subject to continued service.

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-f0d5d7406b5c.html
Robert F. Werner, Chief Accounting Officer at Twist Bioscience Corp (TWST), acquired 8,439 performance stock units on November 12, 2026, after target criteria were met. Of these, 60% are subject to time-based vesting and will fully vest on September 30, 2027, contingent upon his continued service. Following this transaction, his direct holdings in the company amount to 51,208 shares.

T. Rowe Price reports a Twist Bioscience (TWST) stake above its sole voting power of 5.74M shares.

https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-4899d482e4b1.html
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a 9.2% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 6,084,637 shares. The filing indicates T. Rowe Price has sole voting power over 5,738,489 shares and sole dispositive power over all 6,084,637 shares. The firm also explicitly states that the report is not an admission of beneficial ownership and expressly denies being the beneficial owner.

Twist Bioscience Corporation (NASDAQ:TWST): When Will It Breakeven?

https://www.moomoo.com/news/post/1004679391/twist-bioscience-corporation-nasdaq-twst-when-will-it-breakeven
This article analyzes Twist Bioscience Corporation's path to profitability, focusing on analyst expectations for its breakeven point. It discusses the company's current financial performance, including a significant net loss, and projects future revenue growth. The analysis suggests Twist Bioscience is expected to reach breakeven around 2028, with varying forecasts among different analysts.

TD Cowen cuts Twist Bioscience stock price target on execution concerns

https://www.investing.com/news/analyst-ratings/td-cowen-cuts-twist-bioscience-stock-price-target-on-execution-concerns-93CH-5025939
TD Cowen has lowered its price target for Twist Bioscience (NASDAQ:TWST) from $190 to $137, while maintaining a Buy rating, citing concerns over the company's initial conservative fiscal 2027 outlook and the need for strong execution to support upside potential. Despite the stock's impressive 282% return over the past year and recent positive Q4 results, other firms like Canaccord and Jefferies have also reduced their price targets, indicating a mixed analyst outlook. Investors are expected to look for significant quarterly beats to confirm that AI growth is genuinely augmenting the company's legacy business.
Advertisement

Cathie Wood’s ARK sells Amazon stock, buys CoreWeave and Twist Bioscience

https://www.investing.com/news/company-news/cathie-woods-ark-sells-amazon-stock-buys-coreweave-and-twist-bioscience-93CH-5023859
Cathie Wood's ARK ETFs made significant trades on November 12, 2026, including a substantial purchase of CoreWeave Inc. and Twist Bioscience Corporation, aligning with investments in AI infrastructure and biotechnology. Concurrently, ARK reduced its holdings in Amazon.com Inc., Palantir Technologies Inc., BYD Company Limited, and Tempus AI Inc., indicating a strategic reallocation of its portfolio. These movements reflect ARK's focus on cutting-edge technology while divesting from some established and AI-driven healthcare companies.

Twist Bioscience Stock Slides as FY27 AI Drug Discovery Guidance Implies Growth Slowdown

https://finance.biggo.com/news/091fd2f3-aaae-4647-a119-d97f0835adb2
Twist Bioscience shares declined despite beating fourth-quarter estimates and issuing a strong fiscal 2027 revenue forecast, primarily due to concerns over a slowdown in its AI drug discovery segment. While the company projects triple-digit order growth and significant capacity expansion, the implied 69% growth rate for AI drug discovery revenue in FY27 is a substantial decrease from the 175% seen in FY26. Investors are focused on execution risks related to capacity additions and the conversion of orders into revenue.

Twist Bioscience Q4 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63186798/twist-bioscience-q4-2026-earnings-call-transcript
Twist Bioscience reported strong Q4 2026 results with revenue up 28% year-over-year to $126.6 million, exceeding initial full-year guidance. The company achieved positive adjusted EBITDA of $2.2 million and saw significant growth in AI-enabled drug discovery revenue, which increased by 175% to $59.1 million. Twist Bioscience is expanding its manufacturing capacity and capabilities, with plans to invest $150 million in capital expenditures over fiscal 2027 and 2028, and forecasts fiscal 2027 revenue between $550 million and $560 million.

Twist Bio slips despite Q4 beat after underwhelming FY27 outlook

https://seekingalpha.com/news/4671482-twist-bioscience-stock-slips-despite-q4-beat
Shares of Twist Bioscience (TWST) declined in premarket trading despite reporting Q4 FY26 results that surpassed Street forecasts. The synthetic biology company's stock fell due to an underwhelming fiscal 2027 guidance provided alongside its earnings report. The company achieved $126.6M in revenue for the quarter.

Twist Bioscience Corporation (TWST) Tops Q4 EPS by 6c, Offers Guidance

https://www.streetinsider.com/Earnings/Twist+Bioscience+Corporation+%28TWST%29+Tops+Q4+EPS+by+6c%2C+Offers+Guidance/27330431.html
Twist Bioscience Corporation (TWST) reported Q4 EPS of ($0.32), exceeding analyst estimates by $0.06, with revenue also surpassing consensus expectations at $126.6 million. The company provided Q1 2027 revenue guidance of $130-132 million and FY2027 revenue guidance of $550-560 million, both above current consensus estimates, alongside a gross margin forecast of approximately 52.5% to 53%.
Advertisement

Twist Bioscience Beats And Exits FY26 At 28% Growth, But An In-Line FY27 Guide Implies Slower Growth Ahead

https://finviz.com/news/421897/twist-bioscience-beats-and-exits-fy26-at-28-growth-but-an-in-line-fy27-guide-implies-slower-growth-ahead
Twist Bioscience (TWST) closed fiscal 2026 with strong fourth-quarter results, beating consensus estimates for both loss per share and revenue, and achieving positive adjusted EBITDA. Despite this strong finish and accelerating revenue growth, the company's fiscal 2027 outlook projects slower growth, particularly in AI revenue, and flat gross margins due to increased depreciation. The market reacted with investor sentiment shifting to negative, reflecting concerns about dilution and the anticipated slowdown in growth.

Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results

https://finviz.com/news/421550/twist-bioscience-announces-fiscal-2026-fourth-quarter-and-full-year-financial-results
Twist Bioscience Corporation announced its financial results and business highlights for the fourth quarter and full fiscal year 2026, which ended September 30, 2026. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss these results and provide a business update. Detailed reports and presentations are available on the investor relations section of their website.

Is Twist Bioscience (TWST) Undervalued After Its New Oncology Research Product Launches?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/is-twist-bioscience-twst-undervalued-after-its-new-oncology
Twist Bioscience (TWST) has launched Twist MRD Express, a new product for personalized molecular residual disease testing in cancer research, further expanding its oncology tools. Despite this, the stock has recently lost momentum, with a 17.3% decline over 30 days, although it boasts a strong 307.93% year-to-date return. Analysts believe TWST is undervalued by about 21% with a fair value of $168.25, while a sales-based valuation suggests it is expensive.

More than 3 million Twist Bioscience (TWST) shares make up State Street's reported stake.

https://www.stocktitan.net/sec-filings/TWST/schedule-13g-twist-bioscience-corp-passive-investment-disclosure-5-653798dafbcf.html
State Street Corporation has reported a 4.6% beneficial stake in Twist Bioscience Corp (TWST), totaling 3,017,072 shares. The filing indicates shared voting power over 2,846,126 shares and shared dispositive power over 3,017,072 shares, with no sole voting or dispositive power. This disclosure, made via a SCHEDULE 13G SEC filing, highlights State Street's significant, passive investment in the biotechnology company.

Twist Bioscience’s CEO and CFO will appear in live webcasts, with replays available for 30 days.

https://www.stocktitan.net/news/TWST/twist-bioscience-to-present-at-upcoming-investor-igm2j2l19dn0.html
Twist Bioscience (NASDAQ: TWST) announced that its CEO, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in upcoming investor conferences. They are scheduled for fireside chats at the Jefferies Global Healthcare Conference on November 17 and the 9th Annual Evercore Healthcare Conference on December 1. Live webcasts of these sessions will be available on the company's investor relations page, with replays accessible for 30 days.
Advertisement

Form 144 Twist Bioscience Corp For: 7 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-twist-bioscience-corp-for-7-november-93CH-4941274
This article from Investing.com announces the filing of Form 144 for Twist Bioscience Corp (TWST) on November 7. Form 144 is a notice of the intent to sell restricted securities. The article provides the company's stock performance details (+0.15%) and is primarily a brief financial update.

A required tax sale leaves Twist Bioscience (TWST) COO Finn holding 180,278 shares directly.

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-ff6179024ab4.html
Twist Bioscience Corp's President and COO, Patrick John Finn, sold 2,565 shares of TWST stock at $135.4020 per share on November 3, 2026. This transaction was not discretionary but was a "sell to cover" sale mandated to fund tax withholding obligations tied to the vesting of Restricted Stock Units. Following this sale, Finn directly holds 180,278 shares of Twist Bioscience.

Twist Bioscience Corporation (TWST) latest stock news and headlines

https://sg.finance.yahoo.com/quote/TWST/news/
This article provides a compilation of recent news and headlines related to Twist Bioscience Corporation (TWST), including its stock performance and various news items from financial outlets. It highlights the company's stock price, trading activity, and a list of related articles discussing earnings, market reports, and product launches like MRD Express. The performance overview also shows significant trailing total returns for TWST compared to the S&P 500.

Twist Bioscience (TWST) CEO sells 4,573 shares to cover stock-vesting taxes, not discretionarily.

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-411314a53bee.html
Twist Bioscience CEO Emily M. Leproust sold 4,573 common shares on November 3, 2026, for $135.4020 per share. This sale was explicitly stated as non-discretionary, intended solely to cover tax withholding obligations tied to the vesting of restricted stock units under the company's equity incentive plans. Following the transaction, Leproust directly holds 558,187 common shares.

Tax withholding prompts a nondiscretionary 148-share sale at Twist Bioscience (TWST).

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-355d7992f88d.html
Robert F. Werner, Chief Accounting Officer at Twist Bioscience (TWST), sold 148 shares of common stock on November 3, 2026, for $135.4020 per share. This sale was non-discretionary, mandated to cover tax withholding obligations associated with the vesting of restricted stock units under the company's equity incentive plans. After the transaction, Werner directly holds 42,769 shares.
Advertisement

A Fidelity trust has a 5.2% interest in Twist Bioscience (TWST) as FMR updates its stake disclosure.

https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-7df9b03be270.html
FMR LLC and Abigail P. Johnson reported a 14.4% ownership stake in Twist Bioscience (TWST), amounting to 9,535,193 shares. Within this, Fidelity Global Innovators Investment Trust holds an interest in 3,476,508 shares, representing 5.2% of the outstanding common stock as of September 30, 2026. This disclosure was made via an amended Schedule 13G/A filing with the SEC.

Twist Bioscience Stock Sinks as Bear Cave Raises Valuation Concerns

https://www.benzinga.com/trading-ideas/movers/26/11/62935399/twist-bioscience-stock-sinks-as-bear-cave-raises-valuation-concerns
Twist Bioscience (NASDAQ: TWST) shares plunged following a report from The Bear Cave, owned by Hunterbrook Media, which suggested the company's stock valuation is inflated compared to its fundamentals and rivals. The report highlighted that despite being an "ordinary lab supplier," Twist trades at a premium, faces significant competition, and questioned if a past 95% stock value drop could recur. The stock was down over 10% following the report.

Twist Bioscience slides 10% as Bear Cave report questions valuation

https://www.investing.com/news/stock-market-news/twist-bioscience-slides-10-as-bear-cave-report-questions-valuation-5005196
Shares of Twist Bioscience Corp (NASDAQ:TWST) fell 10% after short-seller The Bear Cave released a report challenging the synthetic biology company's high valuation. The report contends that market optimism, fueled by perceived AI partnerships and a short squeeze, has detached from the company's core business economics, which it views as a life sciences tools vendor in a crowded market. It also suggests that investor interest in AI collaborations may have misinterpreted standard customer relationships as strategic alliances, leading to skepticism about the stock's recent ascent given competitive headwinds.

Should New Cancer Research Tools Require Action From Twist Bioscience (TWST) Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/should-new-cancer-research-tools-require-action-from-twist-b
Twist Bioscience (TWST) has launched new synthetic DNA and protein tools, Twist MRD Express and Twist Express Screening Antibodies, to accelerate cancer research and antibody discovery. These offerings aim to reduce development times for liquid biopsy, MRD assays, and antibody screening, potentially impacting demand and product mix. Investors should consider if these new tools can help Twist Bioscience expand its customer base and improve profitability without requiring additional capital, especially given its current loss-making status and reliance on a few large customers.

Twist Bioscience (TWST) Could Be 17% Undervalued As New Product Launches Lift Attention

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/twist-bioscience-twst-could-be-17-undervalued-as-new-product
Twist Bioscience (TWST) has launched two new products, Twist MRD Express and Twist Express Screening Antibodies, which are designed to accelerate cancer diagnostics and drug discovery. The company's stock has seen an 8.73% increase in one day, reaching US$140.30, despite a 25.64% drop over the last 30 days. Analysts suggest the company may be 17% undervalued, with a fair value of $168.25, while acknowledging risks related to unproven profitability and a concentrated customer base.
Advertisement

An officer at Twist Bioscience (TWST) proposes selling 2,565 shares, partly to cover taxes.

https://www.stocktitan.net/sec-filings/TWST/144-twist-bioscience-corp-sec-filing-c5c7e3845bc9.html
Patrick John Finn, an officer at Twist Bioscience (TWST), has filed a Form 144 proposing to sell 2,565 common shares with an aggregate market value of $347,305.36. This sale, facilitated by Fidelity Brokerage Services LLC, is partly intended to cover a tax obligation from a vested equity award distribution. Finn has also reported several prior common-stock sales between August and October 2026.

A proposed 148-share sale at Twist Bioscience (TWST) includes shares to cover a tax obligation.

https://www.stocktitan.net/sec-filings/TWST/144-twist-bioscience-corp-sec-filing-4b404e8325bc.html
Robert F. Werner, an officer at Twist Bioscience Corp. (TWST), has proposed selling 148 common shares with an aggregate market value of $20,039.45. This sale, listed for November 3, 2026, is intended to cover a tax obligation from a vested equity award distribution. The filing also details Werner's earlier sales between August and October 2026.

A planned 949-share sale at Twist Bioscience (TWST) includes shares to cover officer Dennis H. Cho's taxes.

https://www.stocktitan.net/sec-filings/TWST/144-twist-bioscience-corp-sec-filing-7f398a562a43.html
Twist Bioscience officer Dennis H. Cho plans to sell 949 common shares of TWST, valued at approximately $128,496.21, around November 3, 2026. This sale includes shares specifically designated to cover tax obligations arising from a vested equity award distribution. The filing also details seven previous common-stock sales by Mr. Cho between August and October 2026.

Twist Bioscience (TWST) Stock Looks Richly Valued As Its 7x Run Continues

https://ca.finance.yahoo.com/news/twist-bioscience-twst-stock-looks-090908147.html
Twist Bioscience (TWST) stock has surged roughly sevenfold over the past three years, prompting questions about its valuation relative to current and projected sales. While new product launches like Twist MRD Express and Twist Express Screening Antibodies could fuel future growth, the stock currently trades at a P/S ratio of about 18.7x, significantly higher than the biotech industry average. This high valuation suggests the company may be overvalued based on its current fundamentals and risk profile, with community narratives divided between significant upside and stretched expectations.

Notice of Proposed Derivative Settlement: Twist Bioscience Corporation

https://www.stocktitan.net/news/TWST/notice-of-proposed-derivative-settlement-twist-bioscience-ack8nu3cm7kx.html
A summary notice has been issued regarding a proposed derivative settlement for Twist Bioscience Corporation (NASDAQ: TWST). The settlement, awaiting approval from the U.S. District Court for the District of Delaware, includes corporate governance reforms aimed at addressing claims made in the derivative action. A settlement hearing is scheduled for January 22, 2027, at 10:00 a.m. EST, where the Court will consider the fairness of the settlement and requests for attorneys' fees and service awards.
Advertisement

Twist Bioscience (TWST) Debuts MRD Express For Faster Personalized Cancer Panel Research

https://finance.yahoo.com/healthcare/articles/twist-bioscience-twst-debuts-mrd-032210477.html
Twist Bioscience (TWST) has launched Twist MRD Express, a new personalized molecular residual disease panel service aimed at accelerating cancer research. This service provides rapid production of custom MRD detection panels for oncology and liquid biopsy studies, leveraging the company's DNA manufacturing capabilities. The introduction of MRD Express supports Twist Bioscience's product diversification strategy, although the article notes that it does not resolve existing concerns regarding ongoing losses and share price volatility.

Twist Bioscience Corporation Tokenized Stock (Ondo) price today, TWSTon to USD live price, marketcap and chart

https://coinmarketcap.com/currencies/twist-bioscience-corporation-tokenized-stock-ondo/
This page on CoinMarketCap provides a live price and market capitalization overview for Twist Bioscience Corporation Tokenized Stock (Ondo), identified by the ticker TWSTon. It details the total and circulating supply of TWSTon, along with contract information and tags related to tokenized assets and the Solana Ecosystem. The page also features trending real-world assets and popular cryptocurrencies.

Twist Bioscience Launches Custom MRD Panels for Cancer Assay Development

https://clpmag.com/disease-states/cancer/twist-bioscience-launches-custom-mrd-panels-rapid-turnaround/
Twist Bioscience Corporation has introduced Twist MRD Express, a new service offering custom molecular residual disease (MRD) panels with manufacturing turnaround times as short as one day. These panels are designed to aid cancer researchers in developing tumor-informed MRD assays by tracking patient-specific tumor variants with high sensitivity and speed. The platform integrates high-throughput manufacturing, bioinformatics assistance, and e-commerce ordering to support the scaling needs of MRD providers.

Twist Bioscience Launches MRD Express with Rapid Turnaround Time

https://www.morningstar.com/news/business-wire/20261029639258/twist-bioscience-launches-mrd-express-with-rapid-turnaround-time
Twist Bioscience Corporation has launched Twist MRD Express, custom panels designed for cancer researchers to investigate tumor-associated genomic variants with rapid turnaround times. This new offering aims to combine the high sensitivity of tumor-informed molecular residual disease (MRD) detection with the speed and simplicity traditionally associated with tumor-naïve methods. The panels can include up to 10,000 probes and support high-throughput production, enabling researchers to scale their studies and assay development efficiently.

Twist Bioscience launches rapid MRD cancer research panel

https://www.streetinsider.com/Corporate+News/Twist+Bioscience+launches+rapid+MRD+cancer+research+panel/27253303.html
Twist Bioscience has launched Twist MRD Express, a new line of custom panels for cancer researchers. These panels are designed to rapidly detect molecular residual disease (MRD) with turnaround times as short as one day, eliminating the traditional trade-off between sensitivity and speed. The product offers bioinformatics support, e-commerce ordering, and uses Twist's silicon-based DNA synthesis platform for manufacturing.
Advertisement

Twist Bioscience (TWST) COO holds 182,843 shares directly after required tax-related sale.

https://www.stocktitan.net/sec-filings/TWST/form-4-twist-bioscience-corp-insider-trading-activity-344c8d744e15.html
Twist Bioscience Corp's President and COO, Patrick John Finn, sold 2,245 shares of common stock on October 23, 2026, to cover tax withholding obligations from vested Restricted Stock Units. This was a mandated "sell to cover" transaction, not a discretionary trade, and leaves him with 182,843 shares held directly. The sale was priced at $134.5890 per share.

Form 144 Twist Bioscience Corp For: 23 October By Investing.com

https://au.investing.com/news/stock-market-news/form-144-twist-bioscience-corp-for-23-october-93CH-4712107
This article announces that Twist Bioscience Corp (TWST) filed a Form 144 on October 23rd. The brief report from Investing.com indicates that the company's stock was up 3.28% at the time of publication. The article does not provide further details regarding the nature of the Form 144 filing.

Twist Bioscience | 4: Statement of changes in beneficial ownership of securities-Officer Green Paula

https://www.moomoo.com/news/notice/1000623484/statement-of-changes-in-beneficial-ownership-of-securities-officer-green
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Paula Green, an officer at Twist Bioscience. It indicates a change in her beneficial ownership of the company's securities.

A proposed 2,245-share sale at Twist Bioscience (TWST) includes shares to cover an equity-award tax bill.

https://www.stocktitan.net/sec-filings/TWST/144-twist-bioscience-corp-sec-filing-d9150e6b29f1.html
An officer at Twist Bioscience (TWST), Finn Patrick John, has proposed selling 2,245 common shares worth approximately $302,153.21. This sale, scheduled for October 23, 2026, is primarily to cover a tax obligation arising from the settlement of a vested equity award distribution. The shares originate from restricted stock vesting that occurred on October 22, 2026.

Form 144 Twist Bioscience Corp For: 23 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-twist-bioscience-corp-for-23-october-93CH-4929383
This article announces the filing of Form 144 for Twist Bioscience Corp (TWST) on October 23, 2026. The Form 144 is a notice of the intent to sell restricted stock by insiders or affiliates. The article indicates a 3.81% increase in TWST's stock.
Advertisement

Twist Bioscience Corporation Estimates – NASDAQ:TWST

https://www.tradingview.com/symbols/NASDAQ-TWST/financials-estimates/
This page provides financial actuals and estimates for Twist Bioscience Corporation (NASDAQ: TWST), allowing users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.

Twist Bioscience Corp. Estimates – XETR:0ME

https://www.tradingview.com/symbols/XETR-0ME/financials-estimates/
This article provides an overview of Twist Bioscience Corp. (XETR:0ME) financials and estimates on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Twist Bioscience Corp. Dividends – XETR:0ME

https://www.tradingview.com/symbols/XETR-0ME/financials-dividends/
The article provides information about Twist Bioscience Corp. (XETR:0ME) dividends. It is presented as a section within TradingView's financial data offerings, indicating that there are no current trades or dividend data available for the company. The content primarily consists of navigation links and disclaimers related to data provision by FactSet and ICE Data Services.

TD Cowen lifts target to USD 190 for Twist Bioscience stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/td-cowen-lifts-target-to-usd-190-for-twist-bioscience-stock/70373647
TD Cowen has raised its price target for Twist Bioscience (TWST) stock to USD 190, up from USD 115, while maintaining a Buy rating. The increase follows the company's fiscal third-quarter revenue of USD 118.38 million and a USD 300 million public offering. The analyst firm emphasizes that stronger fundamentals and execution towards profitability are necessary to validate the stock's outperformance, as the company targets adjusted EBITDA breakeven in the fourth fiscal quarter.

Form 144 Twist Bioscience Corp For: 18 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-twist-bioscience-corp-for-18-october-93CH-2742467
Investing.com reported on a Form 144 filing for Twist Bioscience Corp (TWST), specifically for transactions that occurred on October 18. The article, published on October 19, 2026, simply announces the filing without providing further details about the nature of the transactions. Twist Bioscience Corp's stock was noted to be down 4.51% at the time of publication.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement